Prognostic role of CMR in patients presenting with ventricular arrhythmias

JACC Cardiovasc Imaging. 2013 Mar;6(3):335-44. doi: 10.1016/j.jcmg.2012.09.012. Epub 2013 Feb 20.

Abstract

Objectives: The goal of this study was to explore whether fibrosis detected by late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) is an independent predictor of hard cardiovascular events in patients presenting with ventricular arrhythmia.

Background: In patients at risk of sudden cardiac death, risk stratification for device therapy remains challenging.

Methods: A total of 373 consecutive patients with sustained ventricular tachycardia (VT) (n = 204) or nonsustained ventricular tachycardia (NSVT) (n = 169) underwent LGE-CMR. The group was prospectively followed up for a median of 2.6 years (range 11 months to 11 years). The predetermined endpoint was a composite of cardiac death/arrest, new episode of sustained VT, or appropriate implantable cardioverter-defibrillator discharge.

Results: Mean left ventricular (LV) ejection fraction (EF) was 60 ± 13%. The presence of fibrosis was a strong and independent predictor of the primary outcome for the whole group (hazard ratio [HR]: 3.3, 95% confidence interval [CI]: 1.8 to 5.8, p < 0.001). In the sustained VT subset, both LV fibrosis and severely impaired systolic function (LVEF <35%) were significant independent predictors in the multivariate model (HR: 3.0, 95% CI: 1.4 to 6.2, p = 0.001; and HR: 2.5, 95% CI: 1.1 to 6.2, p = 0.038, respectively). In the NSVT subset, the presence of fibrosis was the only independent predictor of the endpoint (HR: 4.2, 95% CI: 1.7 to 10.1, p = 0.006).

Conclusions: LGE-CMR-detected fibrosis is an independent predictor of adverse outcomes in patients with ventricular arrhythmia and may have an important role in risk stratification. (The Prognostic Significance of Fibrosis Detection in Ischemic and Non-Ischemic Cardiomyopathy; NCT00930735).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Chi-Square Distribution
  • Contrast Media
  • Death, Sudden, Cardiac / etiology
  • Defibrillators, Implantable
  • Disease-Free Survival
  • Electric Countershock / instrumentation
  • Female
  • Fibrosis
  • Humans
  • Kaplan-Meier Estimate
  • Magnetic Resonance Imaging, Cine*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Myocardium / pathology*
  • Organometallic Compounds
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Stroke Volume
  • Systole
  • Tachycardia, Ventricular / complications
  • Tachycardia, Ventricular / diagnosis*
  • Tachycardia, Ventricular / mortality
  • Tachycardia, Ventricular / pathology
  • Tachycardia, Ventricular / physiopathology
  • Tachycardia, Ventricular / therapy
  • Time Factors
  • Ventricular Function, Left

Substances

  • Contrast Media
  • Organometallic Compounds
  • gadobutrol

Associated data

  • ClinicalTrials.gov/NCT00930735